Renal allograft rejection--in situ demonstration of cytotoxic intratubular cells.

Important note: Information in this article was accurate in 1996. The state of the art may have changed since the publication date.

Renal allograft rejection--in situ demonstration of cytotoxic intratubular cells.

Transplantation. 1996 May 27;61(10):1546-9. Unique Identifier : AIDSLINE MED/96224215
Robertson H; Wheeler J; Kirby JA; Morley AR; Department of Microbiology, The Medical School, University of; Newcastle upon Tyne, United Kingdom.

Abstract: A nonisotopic in situ hybridization method to detect perforin mRNA was developed in cytospin preparations of IL-2-stimulated normal human lymphocytes and applied to formalin-fixed acutely rejected renal transplant material. Individual cells expressing perforin mRNA were localized in severely damaged tubular areas, and a number of these cells appeared to be located inside the tubular basement membrane in close association with tubular epithelial cells. Immunoperoxidase staining in acetone-fixed cryostat sections of acutely rejected kidney confirmed that a considerable proportion of infiltrating cells was CD8+; many of these were in an intratubular location. In addition, perforin protein was identified in individual cells in similar locations to perforin mRNA-positive cells. Again, some intratubular cells were identified. Our findings illustrate that these cells can be fully activated with definite cytotoxic potential. Previously we have demonstrated that T lymphocytes proliferate within the tubular compartment during tubulitis, a characteristic condition in acute renal allograft rejection, and that there is associated tubular epithelial cell proliferation. In this study we think that we have further clarified the consequences of invasion of tubules by lymphoid cells. Our in situ hybridization method in rapid and convenient and may be applied to archival material.

Keywords: Acute Disease Base Sequence Cytotoxicity, Immunologic CD8-Positive T-Lymphocytes/*IMMUNOLOGY DNA Primers/CHEMISTRY Graft Rejection/*DIAGNOSIS Human Immunity, Cellular In Situ Hybridization Kidney Transplantation/*IMMUNOLOGY Kidney Tubules/IMMUNOLOGY Membrane Glycoproteins/GENETICS Molecular Sequence Data RNA, Messenger/GENETICS Support, Non-U.S. Gov't JOURNAL ARTICLE
960930
M9690870

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1996. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1996. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .